CompletedNCT01140620
Ketamine and Risperidone Effects on Thinking and Memory
About this title
Read the official source — NCT01140620Medication studyAges 18–45United KingdomSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- London and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJune 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 87
- Sponsor
- University of Manchester
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United Kingdom
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT01140620
- Official title
Show the full official title
Effects of NMDA Receptor Antagonism on Cognitive Processes in Healthy Volunteers and Its Reversal by a Dopamine Antagonist: Comparison to Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London · Manchester · Cardiff
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Manchester, a university.
Did this study involve medication?
Yes. The study involved medication, including ketamine, risperidone, saline and placebo risperidone.
Who was this study for?
Listed age limits: 18 years to 45 years.
